SynthesisArthritis research & therapy2014
A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility.
Synthesis in Arthritis research & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Unfolding the pathogenesis of scleroderma through genomics and epigenomics.Journal of autoimmunity · 2017Pooled it
- Comprehensive Evaluation of the Genetic Basis of Keratoconus: New Perspectives for Clinical Translation.Investigative ophthalmology & visual science · 2024Article
- Neurological, cardiac, musculoskeletal, and renal manifestations of scleroderma along with insights into its genetics, pathophysiology, diagnostic, and therapeutic updates.Health science reports · 2024Article
- Updates on genetics in systemic sclerosis.Inflammation and regeneration · 2021Review
- Molecular "omic" signatures in systemic sclerosis.European journal of rheumatology · 2020Review
- The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review.Journal of autoimmunity · 2020Review
- Towards a Better Classification and Novel Therapies Based on the Genetics of Systemic Sclerosis.Current rheumatology reports · 2019Review
- Deciphering the Potential Pharmaceutical Mechanism of GUI-ZHI-FU-LING-WAN on Systemic Sclerosis based on Systems Biology Approaches.Scientific reports · 2019Article
- More miles on the clock: Neighbourhood stressors are associated with telomere length in a longitudinal study.PloS one · 2019Article
- Adipocyte-specific Repression of PPAR-gamma by NCoR Contributes to Scleroderma Skin Fibrosis.Arthritis research & therapy · 2018Article
- Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations.PloS one · 2018Article
- TNIP1 in Autoimmune Diseases: Regulation of Toll-like Receptor Signaling.Journal of immunology research · 2018Review
- Current perspectives on the immunopathogenesis of systemic sclerosis.ImmunoTargets and therapy · 2016Review
- Identification of Rare Variants in ATP8B4 as a Risk Factor for Systemic Sclerosis by Whole-Exome Sequencing.Arthritis & rheumatology (Hoboken, N.J.) · 2016Article
- Genetics of systemic sclerosis: recent advances.Current opinion in rheumatology · 2015Review
- Genetics of systemic sclerosis.Seminars in immunopathology · 2015Review
- A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosis.Arthritis research & therapy · 2015Article
- Recent advances in the genetics of systemic sclerosis: toward biological and clinical significance.Current rheumatology reports · 2015Review
- Pathogenesis of Systemic Sclerosis.Frontiers in immunology · 2015Review
- The role of genetics and epigenetics in the pathogenesis of systemic sclerosis.Nature reviews. Rheumatology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 20 institutions in 6 countries.
Funding
Abstract
introductionA recent genome-wide association study (GWAS) comprising a French cohort of systemic sclerosis (SSc) reported several non-HLA single-nucleotide polymorphisms (SNPs) showing a nominal association in the discovery phase. We aimed to identify previously overlooked susceptibility variants by using a follow-up strategy.
methodsSixty-six non-HLA SNPs showing a P value <10⁻⁴ in the discovery phase of the French SSc GWAS were analyzed in the first step of this study, performing a meta-analysis that combined data from the two published SSc GWASs. A total of 2,921 SSc patients and 6,963 healthy controls were included in this first phase. Two SNPs, PPARG rs310746 and CHRNA9 rs6832151, were selected for genotyping in the replication cohort (1,068 SSc patients and 6,762 healthy controls) based on the results of the first step. Genotyping was performed by using TaqMan SNP genotyping assays.
resultsWe observed nominal associations for both PPARG rs310746 (PMH = 1.90 × 10⁻⁶, OR, 1.28) and CHRNA9 rs6832151 (PMH = 4.30 × 10⁻⁶, OR, 1.17) genetic variants with SSc in the first step of our study. In the replication phase, we observed a trend of association for PPARG rs310746 (P value = 0.066; OR, 1.17). The combined overall Mantel-Haenszel meta-analysis of all the cohorts included in the present study revealed that PPARG rs310746 remained associated with SSc with a nominal non-genome-wide significant P value (PMH = 5.00 × 10⁻⁷; OR, 1.25). No evidence of association was observed for CHRNA9 rs6832151 either in the replication phase or in the overall pooled analysis.
conclusionOur results suggest a role of PPARG gene in the development of SSc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.